Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, is likely to become a biotech cautionary tale into the future but the next twist in the tale was revealed to be it securing a new lead candidate, this time in Parkinson’s disease.
![Zonder mens geen merk: waarom AI nooit merkvertrouwen kan automatiseren [onderzoek]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/11/206-80x60.jpg)
Reageer